{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:24:26Z","timestamp":1777893866214,"version":"3.51.4"},"reference-count":41,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Society for Follow-up of Rheumatic Diseases (ROHIDER)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: CT-P13 is a biosimilar version of infliximab, a monoclonal antibody. In individuals with ankylosing spondylitis (AS), CT-P13 has been shown to be effective and to have a well-tolerated safety profile. The aim of this study was to evaluate the long-term drug persistence, safety, and efficacy of infliximab biosimilar CT-P13 in patients with AS undergoing first-line (1st-line) and later (\u22652nd-line) treatment in clinical practice. Methods: We performed an observational cohort study that included AS patients based on the biological drug database in the TURKBIO Registry between 2014 and 2021. The patients were divided into two groups: those receiving CT-P13 as first-line treatment or as a switch (\u22652nd-line) from another TNF inhibitor (TNFi). Standard disease activity metrics were used to assess the effectiveness of CT-P13, and drug retention rates were investigated. Results: There were 179 AS patients using CT-P13 (47.4% male, mean age: 42.9 \u00b1 11.3 years). Of these patients, 123 (68.7%) were receiving CT-P13 as a first-line treatment. The mean length of treatment was 3.5 years. CT-P13 drug retention rates in the general patient population were 58.6% and 48.2% in the first-line and \u2265second-line treatment, respectively, after 3 years of follow-up. The most common reason for CT-P13 treatment discontinuation was lack of efficacy. The first-line CT-P13 group had statistically substantially higher ASAS20\/40 response rates at three and six months. Nonetheless, both groups\u2019 response rates at one year were comparable. Conclusions: In this real-world data analysis, AS patients who were TNFi na\u00efve (1st-line) and subsequently treated (\u22652nd-line) with CT-P13 showed encouraging drug retention rates with acceptable long-term effectiveness and safety.<\/jats:p>","DOI":"10.3390\/jcm13237266","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T08:24:14Z","timestamp":1732868654000},"page":"7266","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of CT-P13 as First- and Second-Line Treatment in Patients with Ankylosing Spondylitis"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6266-2454","authenticated-orcid":false,"given":"Sadettin","family":"Uslu","sequence":"first","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Celal Bayar University, 45140 Manisa, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8679-2130","authenticated-orcid":false,"given":"Semih","family":"G\u00fclle","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Dokuz Eylul University, 35220 Izmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gercek","family":"Sen","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Dokuz Eylul University, 35220 Izmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4741-4908","authenticated-orcid":false,"given":"Sedat","family":"Capar","sequence":"additional","affiliation":[{"name":"Department of Statistics, Faculty of Science, Dokuz Eylul University, 35390 Izmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soner","family":"Senel","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Erciyes University, 38030 Kayseri, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ediz","family":"Dalk\u0131l\u0131c","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Uludag University, 16285 Bursa, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Servet","family":"Akar","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, K\u00e2tip Celebi University, 35620 Izmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4995-430X","authenticated-orcid":false,"given":"S\u00fcleyman Serdar","family":"Koca","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Firat University, 23119 Elazig, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdurrahman","family":"Tufan","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Gazi University, 06570 Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayten","family":"Yazici","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Kocaeli University, 41001 Kocaeli, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sema","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Selcuk University, 42250 Konya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nevsun","family":"Inanc","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Marmara University, 34854 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5118-9307","authenticated-orcid":false,"given":"Merih","family":"Birlik","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Dokuz Eylul University, 35220 Izmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilek","family":"Solmaz","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, K\u00e2tip Celebi University, 35620 Izmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayse","family":"Cefle","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Kocaeli University, 41001 Kocaeli, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berna","family":"Goker","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Gazi University, 06570 Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haner","family":"Direskeneli","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Marmara University, 34854 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Servet","family":"Yolbas","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Inonu University, 44000 Malatya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Steen Krogh","sequence":"additional","affiliation":[{"name":"Economics, Zitelab Aps, 2000 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neslihan","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Bilim University, 34394 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00fckran","family":"Erten","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Yildirim Beyazit University, 06760 Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cemal","family":"Bes","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Istanbul Basaksehir Cam and Sakura Hospital, 34758 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozg\u00fcl","family":"Soysal G\u00fcnd\u00fcz","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Celal Bayar University, 45140 Manisa, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Akif","family":"Ozt\u00fcrk","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Gazi University, 06570 Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seminur","family":"Haznedaroglu","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Gazi University, 06570 Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sule","family":"Yavuz","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Marmara University, 34854 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatos","family":"Onen","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Dokuz Eylul University, 35220 Izmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7737-4180","authenticated-orcid":false,"given":"Ismail","family":"Sari","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Dokuz Eylul University, 35220 Izmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The Assessment of SpondyloArthritis International Society Classification Criteria for Peripheral Spondyloarthritis and for Spondyloarthritis in General","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.46497\/ArchRheumatol.2024.10391","article-title":"Biological Treatment in Elderly and Young Patients with Ankylosing Spondylitis: TURKBIO Real-Life Data Results","volume":"39","author":"Uslu","year":"2024","journal-title":"Arch. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrrheum.2015.110","article-title":"Biosimilars in Rheumatology: Current Perspectives and Lessons Learnt","volume":"11","author":"Kay","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s40259-014-0094-1","article-title":"A Review of CT-P13: An Infliximab Biosimilar","volume":"28","author":"McKeage","year":"2014","journal-title":"BioDrugs"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/annrheumdis-2015-208783","article-title":"Efficacy and Safety of Switching from Reference Infliximab to CT-P13 Compared with Maintenance of CT-P13 in Ankylosing Spondylitis: 102-Week Data from the PLANETAS Extension Study","volume":"76","author":"Park","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A Randomised, Double-Blind, Multicentre, Parallel-Group, Prospective Study Comparing the Pharmacokinetics, Safety, and Efficacy of CT-P13 and Innovator Infliximab in Patients with Ankylosing Spondylitis: The PLANETAS Study","volume":"72","author":"Park","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13075-016-0930-4","article-title":"Comparable Long-Term Efficacy, as Assessed by Patient-Reported Outcomes, Safety and Pharmacokinetics, of CT-P13 and Reference Infliximab in Patients with Ankylosing Spondylitis: 54-Week Results from the Randomized, Parallel-Group PLANETAS Study","volume":"18","author":"Park","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"ref_8","first-page":"2286","article-title":"A New Approach to Defining Disease Status in Ankylosing Spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Assessment of SpondyloArthritis international Society Ankylosing Spondylitis Disease Activity Score (ASDAS): Defining Cut-off Values for Disease Activity States and Improvement Scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1007\/s10067-006-0479-8","article-title":"Brazilian-Portuguese Version of the Health Assessment Questionnaire for Spondyloarthropathies (HAQ-S) in Patients with Ankylosing Spondylitis: A Translation, Cross-Cultural Adaptation, and Validation","volume":"26","author":"Shinjo","year":"2007","journal-title":"Clin. Rheumatol."},{"key":"ref_11","first-page":"2281","article-title":"A New Approach to Defining Functional Ability in Ankylosing Spondylitis: The Development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin","year":"1994","journal-title":"J. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.62.9.817","article-title":"ASAS Working Group International ASAS Consensus Statement for the Use of Anti-Tumour Necrosis Factor Agents in Patients with Ankylosing Spondylitis","volume":"62","author":"Braun","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/rheumatology\/kex277","article-title":"Biosimilars in Rheumatology: A Review of the Evidence and Their Place in the Treatment Algorithm","volume":"56","author":"Skapenko","year":"2017","journal-title":"Rheumatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2015-208786","article-title":"Efficacy and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Rheumatoid Arthritis: Comparison between Switching from Reference Infliximab to CT-P13 and Continuing CT-P13 in the PLANETRA Extension Study","volume":"76","author":"Yoo","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jbspin.2017.10.003","article-title":"Switching from Originator Infliximab to Biosimilar CT-P13 in Real-Life: The Weight of Patient Acceptance","volume":"85","author":"Scherlinger","year":"2018","journal-title":"Jt. Bone Spine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/ar1941","article-title":"Survival of TNF Antagonists in Spondylarthritis Is Better than in Rheumatoid Arthritis. Data from the Spanish Registry BIOBADASER","volume":"8","author":"Carmona","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/1060028016682330","article-title":"Reasons for Discontinuation and Adverse Effects of TNF\u03b1 Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis","volume":"51","author":"Viney","year":"2017","journal-title":"Ann. Pharmacother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3346\/jkms.2014.29.9.1205","article-title":"Drug Survival Rates of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis","volume":"29","author":"Kang","year":"2014","journal-title":"J. Korean Med. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/annrheumdis-2014-206616","article-title":"The Effect of Comedication with Conventional Synthetic Disease Modifying Antirheumatic Drugs on TNF Inhibitor Drug Survival in Patients with Ankylosing Spondylitis and Undifferentiated Spondyloarthritis: Results from a Nationwide Prospective Study","volume":"74","author":"Lie","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_20","first-page":"958","article-title":"Anti-TNF Therapy of Ankylosing Spondylitis in Clinical Practice. Results from the Czech National Registry ATTRA","volume":"27","author":"Pavelka","year":"2009","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A Randomised, Double-Blind, Parallel-Group Study to Demonstrate Equivalence in Efficacy and Safety of CT-P13 Compared with Innovator Infliximab When Coadministered with Methotrexate in Patients with Active Rheumatoid Arthritis: The PLANETRA Study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.55563\/clinexprheumatol\/z0va6o","article-title":"Retention Rate and Long-Term Safety of Biosimilar CT-P13 in Patients with Ankylosing Spondylitis: Data from the Korean College of Rheumatology Biologics Registry","volume":"38","author":"Kim","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12026-016-8843-5","article-title":"Safety, Efficacy and Immunogenicity of Switching from Innovator to Biosimilar Infliximab in Patients with Spondyloarthritis: A 6-Month Real-Life Observational Study","volume":"65","author":"Benucci","year":"2017","journal-title":"Immunol. Res."},{"key":"ref_24","first-page":"i125","article-title":"158 Infliximab Biosimilars\u2014Switching Remicade to Remsima in Routine Care: Patient Acceptability and Early Outcome Data","volume":"55","author":"Malaiya","year":"2016","journal-title":"Rheumatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11926-017-0658-4","article-title":"Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician","volume":"19","author":"Moots","year":"2017","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1007\/s10198-014-0595-3","article-title":"Budget Impact Analysis of Biosimilar Infliximab (CT-P13) for the Treatment of Rheumatoid Arthritis in Six Central and Eastern European Countries","volume":"15","author":"Brodszky","year":"2014","journal-title":"Eur. J. Heal. Econ. HEPAC Heal. Econ. Prev. Care"},{"key":"ref_27","first-page":"97","article-title":"Short-Term Costs Associated with Non-Medical Switching in Autoimmune Conditions","volume":"37","author":"Gibofsky","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s12325-015-0233-1","article-title":"The Budget Impact of Biosimilar Infliximab (Remsima\u00ae) for the Treatment of Autoimmune Diseases in Five European Countries","volume":"32","author":"Jha","year":"2015","journal-title":"Adv. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"A558","DOI":"10.1016\/j.jval.2013.08.1465","article-title":"Introduction of an Infliximab Biosimilar (CT-P13): A Five-Year Budget Impact Analysis for the Treatment of Rheumatoid Arthritis in Ireland","volume":"16","author":"McCarthy","year":"2013","journal-title":"Value Health"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of Certolizumab Pegol on Signs and Symptoms of Axial Spondyloarthritis Including Ankylosing Spondylitis: 24-Week Results of a Double-Blind Randomised Placebo-Controlled Phase 3 Study","volume":"73","author":"Braun","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from Originator Infliximab to Biosimilar CT-P13 Compared with Maintained Treatment with Originator Infliximab (NOR-SWITCH): A 52-Week, Randomised, Double-Blind, Non-Inferiority Trial","volume":"389","author":"Olsen","year":"2017","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/14712598.2016.1198765","article-title":"Switch from Infliximab to Infliximab Biosimilar: Efficacy and Safety in a Cohort of Patients with Different Rheumatic Diseases Response to: Nikiphorou E, Kautiainen H, Hannonen P; et al. Clinical Effectiveness of CT-P13 (Infliximab Biosimilar) Used as a Switch from Remicade (Infliximab) in Patients with Established Rheumatic Disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015, 15, 1677\u20131683","volume":"16","author":"Gentileschi","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1002\/art.11104","article-title":"Long-Term Efficacy and Safety of Infliximab in the Treatment of Ankylosing Spondylitis: An Open, Observational, Extension Study of a Three-Month, Randomized, Placebo-Controlled Trial","volume":"48","author":"Braun","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and Safety of Infliximab in Patients with Ankylosing Spondylitis: Results of a Randomized, Placebo-Controlled Trial (ASSERT)","volume":"52","author":"Dijkmans","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of Active Ankylosing Spondylitis with Infliximab: A Randomised Controlled Multicentre Trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.24001","article-title":"Efficacy and Safety of Infliximab in Patients with Ankylosing Spondylitis over a Two-Year Period","volume":"59","author":"Braun","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Martu, M.-A., Maftei, G.-A., Luchian, I., Stefanescu, O.M., Scutariu, M.M., and Solomon, S.M. (2021). The Effect of Acknowledged and Novel Anti-Rheumatic Therapies on Periodontal Tissues\u2014A Narrative Review. Pharmaceuticals, 14.","DOI":"10.3390\/ph14121209"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/conmed-2017-100005","article-title":"Biosimilars: Considerations for Clinical Practice","volume":"1","author":"Azevedo","year":"2017","journal-title":"Considerations Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1586\/1744666X.2015.1090313","article-title":"Biosimilars for the Management of Rheumatoid Arthritis: Economic Considerations","volume":"11","author":"Brodszky","year":"2015","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"82","DOI":"10.5152\/eurjrheum.2022.21060","article-title":"A Real-Life Analysis of Patients with Rheumatologic Diseases on Biological Treatments: Data from TURKBIO Registry","volume":"9","author":"Can","year":"2022","journal-title":"Eur. J. Rheumatol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Uslu, S., Gulle, S., Sen, G., Cefle, A., Yilmaz, S., Kocaer, S.B., Yuce Inel, T., Koca, S.S., Yolbas, S., and Ozturk, M.A. (2024). Assessing Safety and Efficacy of TNFi Treatment in Late Onset Ankylosing Spondylitis: A TURKBIO Registry Study. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-65180-4"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/23\/7266\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:42:32Z","timestamp":1760114552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/23\/7266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":41,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["jcm13237266"],"URL":"https:\/\/doi.org\/10.3390\/jcm13237266","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]}}}